| [1] |
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132.
|
| [2] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
|
| [3] |
Cao W, Chen HD, Yu YW, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J]. Chin Med J, 2021, 134(7):783-791.
|
| [4] |
European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2012, 56(4):908-943.
|
| [5] |
Mazzaferro V, Lencioni R, Majno P. Early hepatocellular carcinoma on the procrustean bed of ablation, resection, and transplantation[J]. Semin Liver Dis, 2014, 34(4):415-426.
|
| [6] |
Lu LC, Cheng AL, Poon RT. Recent advances in the prevention of hepatocellular carcinoma recurrence[J]. Semin Liver Dis, 2014, 34(4):427-434.
|
| [7] |
Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives[J]. Gut, 2014, 63(5):844-855.
|
| [8] |
中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗指南（2022年版）[J]. 中华消化外科杂志, 2022, 21(2):143-168.
|
| [9] |
Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391(10126):1163-1173.
|
| [10] |
Golse N, Radenne S, Rode A, et al. Liver transplantation after neoadjuvant sorafenib therapy: preliminary experience and literature review[J]. Exp Clin Transplant, 2018, 16(2):227-236.
|
| [11] |
Eilard MS, Andersson M, Naredi P, et al. A prospective clinical trial on sorafenib treatment of hepatocellular carcinoma before liver transplantation[J]. BMC Cancer, 2019, 19(1):568.
|
| [12] |
Rozeman EA, Menzies AM, van Akkooi ACJ, et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage Ⅲ melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial[J]. Lancet Oncol, 2019, 20(7):948-960.
|
| [13] |
Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 blockade in resectable lung cancer[J]. N Engl J Med, 2018, 378(21):1976-1986.
|
| [14] |
Powles T, Kockx M, Rodriguez-Vida A, et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial[J]. Nat Med, 2019, 25(11):1706-1714.
|
| [15] |
Chalabi M, Fanchi LF, Dijkstra KK, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers[J]. Nat Med, 2020, 26(4):566-576.
|
| [16] |
Nanda R, Liu MC, Yau C, et al. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial[J]. JAMA Oncol, 2020, 6(5):676-684.
|
| [17] |
Marron TU, Fiel MI, Hamon P, et al. Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2trial[J]. Lancet Gastroenterol Hepatol, 2022, 7(3):219-229.
|
| [18] |
Kaseb AO, Hasanov E, Cao HST, et al. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2022, 7(3):208-218.
|
| [19] |
Ho WJ, Zhu Q, Durham J, et al. Neoadjuvant cabozantinib and nivolumab converts locally advanced HCC into resectable disease with enhanced antitumor immunity[J]. Nat Cancer, 2021, 2(9):891-903.
|
| [20] |
Shi YH, Ji Y, Liu WR, et al. A phaseⅠb/Ⅱ, open-label, multi-center study evaluating the efficacy and safety of neoadjuvant toripalimab injection (JS001) or toripalimab in combination with lenvatinib for patients with resectable hepatocellular carcinoma (HCC)[C/OL]//American Association for Cancer Research Annual Meeting, Philadelphia, 2021[2022-07-18].
URL
|
| [21] |
Saâda-Bouzid E, Defaucheux C, Karabajakian A, et al. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma[J]. Ann Oncol, 2017, 28(7):1605-1611.
|
| [22] |
Zhu XD, Huang C, Shen YH, et al. Downstaging and resection of initially unresectable hepatocellular carcinoma with tyrosine kinase inhibitor and anti-PD-1 antibody combinations[J]. Liver Cancer, 2021, 10(4):320-329.
|